Skip to Content

The Role of ctDNA in Precision Oncology – New Data from the IMPRESS-Norway Study

In this MEDtalk from ESMO 2024, Dr Ingrid Dyvik from Oslo University Hospital, Norway, presents findings from the IMPRESS-Norway trial. This trial evaluates the efficacy of anti-cancer drugs in new indications. Dyvik highlights the role of circulating tumour DNA (ctDNA) in precision oncology.

Ingrid Dyvik

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top